UNSPSC 51322802: Niceritrol

This classification denotes an anti-lipidemic agent with the molecular formula C29H24N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F54EHJ34MV, chemically known as 3-pyridinecarboxylic acid, 2,2-bis(((3-pyridinylcarbonyl)oxy)methyl)-1,3-propanediyl ester but generally known as niceritrol, which bears US NIH Compound Identifier 4476. European Medicines Agency schedules Niceritrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09227MIG.

UNSPSC 51322802 Niceritrol, a Commodity code, represents emergency and critical-care medications that state and local governments procure for fire rescue, emergency medical services, and public health programs. The code encompasses specific injectable pharmaceuticals used in advanced life support protocols—epinephrine, adenosine, diltiazem, labetalol, and similar agents—supplied in regulated quantities with strict expiration and quality-assurance requirements. State and local buyers under this code include city fire departments, county emergency services, state health agencies administering pharmacy benefit programs, and multi-jurisdictional cooperative purchasing alliances. The scope extends beyond single-unit acquisitions to include volume-based supply arrangements, direct-to-manufacturer relationships, and multi-state cooperative contracts that aggregate demand across dozens of participating public entities.

Recent solicitation activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, featuring a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued RFI No. HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating states and localities, with a response deadline of March 26, 2026 and contract effectiveness July 1, 2026. All three solicitations require vendors to meet FDA compliance, cGMP certification, DSCSA requirements, product expiration standards, and comprehensive insurance coverage; Tampa's bid also mandates WCAG 2.2 Level AA accessibility and OSHA Safety Data Sheets.